Clinical_Rounds_in_Endocrinology_Volume_II_-_Pediatric_Endocrinology

404 hyperglycemia (by inhibition of α-cells) and prevents recurrence of hypoglyce- mia (by inhibition of β-cells). When euglycem ...

405 During the initial stage, T-cell-mediated (CD-4 positive) β-cell injury results in insulitis. This stage is characterized by ...

406 Is there a difference in clinical profile of children with T1DM who have paren- tal history of T2DM? Children with T1DM wh ...

407 modalities available for the management of T1DM are summarized in the table given below. Modality Remarks Basal–bolus insuli ...

408 of hypoglycemia, and failure to achieve target HbA1c as compared to basal– bolus regimen. On the contrary, basal–bolus regim ...

409 during hypoglycemia is reduction in intra-islet insulin which is a signal to α-cell to secrete glucagon; this is defective i ...

410 cardiovascular disease (CVD) risk factors, after optimal glycemic control and MNT. Lipid profile should be monitored yearly ...

411 angiogenesis. Gonadal steroids, testosterone, lead to rise in blood pressure, worsening of dyslipidemia, and increase in vas ...

412 How to define diabetic ketoacidosis? The diagnostic criteria for diabetic ketoacidosis (DKA) include blood glucose >250 ...

413 A 16-year-old boy who is a known patient of T1DM presented with altered sen- sorium. On examination, he had mild dehydratio ...

414 What is the most common age of presentation of T2DM in young individuals? Increased prevalence of childhood obesity as a r ...

415 should be carefully examined for other features of insulin resistance (double chin, skin tags, and central obesity), hyperte ...

416 What are the various subtypes of MODY? Various subtypes of MODY are classified on the basis of mutations in genes implicat ...

417 disorders have different etiology, treatment strategy, associated comorbidities, and prognosis. The important differentiatin ...

418 How do hepatocyte nuclear transcription factors regulate insulin secretion and glucose metabolism? Hepatocyte nuclear tran ...

419 How to treat patients with MODY? The basic pathophysiological defect in patients with MODY is β-cell dysfunc- tion (rather ...

420 Is there any difference in antibody profile of patients with LADA and T1DM? The presence of multiple (≥2) islet autoantibo ...

421 T2DM are usually obese, asymptomatic, or mildly symptomatic and may have a family history of T2DM. Further, the presence of ...

422 What is the etiopathogenesis of FCPD? The etiopathogenesis of FCPD remains elusive; however, various theories have been pr ...

423 (85 %) of patients require insulin therapy. Incretin-based therapies should be avoided in these individuals. Pancreatic enzy ...